Next-Gen MRD: Increasing Access to Ultrasensitive ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs

Time: 2:30 pm
day: Conference Day 1

Details:

  • The Pathlight MRD test is an ultrasensitive, cost-effective approach to MRD detection and quantification to <1 PPM using WGS proprietary dPCR methods to track structural variants
  • Structural Variants (SVs) are highly prevalent across indications and are an ideal pancancer biomarker for determining MRD status
  • Clinical studies in breast and ovarian cancers demonstrate improved detection of ctDNA at baseline, during neoadjuvant treatment, post-surgery, and during follow-up, with long lead times to clinical relapse

Speakers:

Patrick Eimerman
Patrick Eimerman